Why Is KESTRA MED TECHNOLOG (KMTS) Stock Down Today?

Kestra Medical Technologies (KMTS) fell 9.60% to $21.75 in early trading on September 15, 2026, following a mixed earnings report and pre-market insider sales. The stock opened with a 9.9% gap down from the previous close of $24.06 and has traded in a narrow range since. The move reflects investor concerns over the company's continued losses and recent selling by directors.

What Happened

Kestra Medical reported first-quarter FY 2027 results that showed a GAAP loss per share of $0.75, missing the consensus estimate of $0.62. Revenue of $31 million exceeded expectations by $1.99 million and rose 59.8% year-over-year. The company raised its full-year 2027 revenue guidance to $141 million from $137 million, while maintaining a target of mid-70% gross margins. Despite these updates, the stock fell sharply in pre-market trading. The Fly reported that Kestra’s shares were down 7% at $22.32 after the earnings miss.

On September 8, three directors, Hanley Conor, Schwartz Jeffrey Lawrence, and Reilly Kevin C, sold shares in the company. The Fly also noted that Kestra’s stock was down 7% in pre-market trading, and Benzinga highlighted the stock as one of several big movers in the session.

What The Data Shows

Kestra Medical’s stock opened at $21.69 and reached an intraday high of $22.05 before retreating to $21.32. The last traded price was $21.75. Volume was 0.0 million shares, or 0.1 times the 3-month average. The stock has declined 6.5% over the last eight sessions, from $25.73 to $24.06. Over the past 90 days, insiders have sold 17 times, totaling $6.5 million. The 52-week range is $17.34 to $30.00. On September 14, the stock printed two fresh 52-week lows.

What To Watch

Kestra Medical’s next key event is its earnings call transcript availability, which was released on September 14. Investors should monitor coverage breadth and any follow-up analyst commentary on the updated guidance and earnings performance.